Biocon acquires Eywa Pharma’s US-based plant for USD 7.7 mn, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The facility is acquired for a total consideration of USD 7.7 million, it added. As part of the acquisition, the existing workforce of the facility will transition into Biocon Generics Inc. The facility has the potential for capacity expansion of up to 2 billion tablets/capsules per year., The facility is acquired for a total consideration of USD 7.7 million, it added. As part of the acquisition, the existing workforce of the facility will transition into Biocon Generics Inc. The facility has the potential for capacity expansion of up to 2 billion tablets/capsules per year., , Read More

Leave a Reply

Your email address will not be published.